Indication
Carcinoid syndrome diarrhea
Carcinoid syndrome diarrhea is a chronic, secretory gastrointestinal complication that occurs in patients with advanced, well-differentiated neuroendocrine tumors, most often originating in the midgut and metastatic to the liver. Read more about Carcinoid syndrome diarrhea
3 drugs 3 manufacturers
Drugs that treat it
Common Carcinoid syndrome diarrhea therapies.
XERMELO (telotristat etiprate)
XERMELO (telotristat etiprate)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonCarcinoid syndrome diarrhea is a chronic, secretory gastrointestinal complication that occurs in patients with advanced, well-differentiated neuroendocrine tumors, most often originating in the midgut and metastatic to the liver.
It develops when tumor cells release excess humoral mediators—predominantly serotonin (5-hydroxytryptamine), along with tachykinins and prostaglandins—directly into the systemic circulation, bypassing hepatic first-pass metabolism.
Within the digestive tract, this hypersecretion stimulates intestinal motility, accelerates gut transit, and promotes colonic electrolyte and water secretion while impairing absorption.
Clinically, it is characterized by frequent, debilitating, watery bowel movements often accompanied by abdominal cramping, tenesmus, and malabsorption, occurring either alongside or independently of other classic carcinoid manifestations like cutaneous flushing.
- nih.gov
Carcinoid syndrome diarrhea is a chronic, secretory gastrointestinal complication that occurs in patients with advanced, well-differentiated neuroendocrine tumors, most often originating in the midgut and metastatic to the liver Clinically, it is characterized by frequent, debilitating, watery bowel movements often accompanied by abdominal cramping, tenesmus, and malabsorption, occurring either alongside or independently of other classic carcinoid manifestations like cutaneous flushing
- nih.gov
Carcinoid syndrome diarrhea is a chronic, secretory gastrointestinal complication that occurs in patients with advanced, well-differentiated neuroendocrine tumors, most often originating in the midgut and metastatic to the liver It develops when tumor cells release excess humoral mediators—predominantly serotonin (5-hydroxytryptamine), along with tachykinins and prostaglandins—directly into the systemic circulation, bypassing hepatic first-pass metabolism Clinically, it is characterized by frequ...
- uspharmacist.com
It develops when tumor cells release excess humoral mediators—predominantly serotonin (5-hydroxytryptamine), along with tachykinins and prostaglandins—directly into the systemic circulation, bypassing hepatic first-pass metabolism
- bmj.com
It develops when tumor cells release excess humoral mediators—predominantly serotonin (5-hydroxytryptamine), along with tachykinins and prostaglandins—directly into the systemic circulation, bypassing hepatic first-pass metabolism
- nih.gov
Clinically, it is characterized by frequent, debilitating, watery bowel movements often accompanied by abdominal cramping, tenesmus, and malabsorption, occurring either alongside or independently of other classic carcinoid manifestations like cutaneous flushing
Personalize your experience
Follow Carcinoid syndrome diarrhea and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.